Study to determine rate of absorption or bioavailability of amphetamine extended-release liquid formulation (AMP XR-OS) in patient with attention-deficit/hyperactivity disorder.

Trial Profile

Study to determine rate of absorption or bioavailability of amphetamine extended-release liquid formulation (AMP XR-OS) in patient with attention-deficit/hyperactivity disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Amphetamines (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Neos Therapeutics
  • Most Recent Events

    • 10 Jan 2018 According to a Neos Therapeutics media release, results from this trial will be presented at the 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD).
    • 30 Nov 2017 New trial record
    • 22 Nov 2017 Results assessing bioavailability of amphetamine after administration of AMP XR-OS to healthy adult volunteers, were published in the Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top